title: Understanding agglomeration of indomethacin during the dissolution of micronised indomethacin mixtures through dissolution and de-agglomeration modeling approaches.
abstract: The purpose of this research was to correlate the state of agglomeration determined by the modeling of dissolution and de-agglomeration profiles, using mixtures of micronised indomethacin designed to have different dissolution rates and extents of particle agglomeration in dissolution media. Dissolution profiles were determined using the USP paddle method. De-agglomeration profiles were obtained from laser diffraction particle sizing of mixtures of indomethacin in dissolution media under non-sink conditions. Data were modeled and key parameters estimated using a non-linear least squares estimation algorithm. The key parameters of initial apparent volume concentrations as dispersed and agglomerated particles, and dissolution rate constants (for dissolution modeling), and the apparent volume concentrations of dispersible and non-dispersible agglomerates and the de-agglomeration rate constant (for de-agglomeration modeling) were related to indomethacin and sodium lauryl sulphate concentrations in the lactose-povidone mixtures. Micronised sodium lauryl sulphate added to the mixture was more effective in de-agglomeration than equivalent concentrations in the dissolution media. An excellent correlation existed between the total initial apparent volume concentration of agglomerates determined by dissolution and de-agglomeration (P=0.98). The use of key parameters estimated from the modeling of dissolution and de-agglomeration profiles provides a useful tool in dosage form development of formulations of poorly water soluble drugs.
authors.affiliation: Department of Pharmaceutics, Victorian College of Pharmacy, Monash University, Parkville, Vic., Australia. peter.stewart@vcp.monash.edu.au
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Stewart
authors.forename: Feng-Ying
authors.initials: FY
authors.lastname: Zhao
mesh_terms: D002626:Chemistry, Pharmaceutical / Q000379:methods*; D007213:Indomethacin / Q000737:chemistry* / Q000493:pharmacokinetics*; D008956:Models, Chemical; D010316:Particle Size; D012995:Solubility
chemical_list: D007213:Indomethacin